Nuvation Bio
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 51
- Market Cap
- $767.6M
- Introduction
Nuvation Bio, Inc. is a biopharmaceutical company tackling some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. The company was founded by David Hung on March 20, 2018 and is headquartered in New York, NY.
Expanded Access Program of Taletrectinib in Patients with Advanced or Metastatic ROS1-Positive NSCLC
- Conditions
- Lung NeoplasmsRespiratory Tract NeoplasmsThoracic NeoplasmsNeoplasms by SiteNeoplasmsLung DiseasesRespiratory Tract DiseasesCarcinomaBronchogenic CarcinomaNon Small Cell Carcinoma of the Lung
- First Posted Date
- 2025-02-24
- Last Posted Date
- 2025-02-26
- Lead Sponsor
- Nuvation Bio Inc.
- Registration Number
- NCT06841874
A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-08-21
- Last Posted Date
- 2025-03-11
- Lead Sponsor
- Nuvation Bio Inc.
- Target Recruit Count
- 138
- Registration Number
- NCT06564324
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China
🇨🇳Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China
Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors
- Conditions
- Pancreatic CancerMetastatic Castration-resistant Prostate Cancer (mCRPC)Advanced Solid TumorPlatinum-resistant Ovarian Cancer (PROC)HER2-negative Breast Cancer
- Interventions
- First Posted Date
- 2024-03-28
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- Nuvation Bio Inc.
- Target Recruit Count
- 466
- Registration Number
- NCT06334432
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸Fred Hutchinson, Seattle, Washington, United States
🇺🇸Karmanos Cancer Center, Detroit, Michigan, United States
Study the Effect of Omeprazole on AB-106 Pharmacokinetics
- Conditions
- Pharmacokinetic Study
- Interventions
- Drug: Multiple administration of omeprazole Single administration of AB-106
- First Posted Date
- 2022-11-08
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Nuvation Bio Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT05609929
- Locations
- 🇨🇳
Shanghai Xuhui Central Hospital, Shanghai, China
A Study of AB-106 in Chinese Healthy Adult Men Evaluated the Effects of Itraconazole and Rifampicin on AB-106 PK
- Conditions
- Solid Tumor
- Interventions
- First Posted Date
- 2022-05-03
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Nuvation Bio Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT05357820
- Locations
- 🇨🇳
Xuanwu Hospital of Capital Medical University, Beijing, China
A Study on the Effect of AB-106 on the Pharmacokinetics of Digoxin
- First Posted Date
- 2022-05-03
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Nuvation Bio Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT05357911
- Locations
- 🇨🇳
Shanghai Xuhui Central Hospital, Shanghai, China
Safusidenib Phase 2 Study in IDH1 Mutant Glioma
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Nuvation Bio Inc.
- Target Recruit Count
- 95
- Registration Number
- NCT05303519
- Locations
- 🇺🇸
St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
- Conditions
- Cancer of OvaryProstatic CancerCastration Resistant Prostatic NeoplasmsBreast TumorCancer of the OvaryProstate CancerCancer of the ProstateTriple-negative Breast CancerCancer of BreastOvary Cancer
- Interventions
- First Posted Date
- 2022-02-23
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- Nuvation Bio Inc.
- Target Recruit Count
- 82
- Registration Number
- NCT05252390
- Locations
- 🇺🇸
The University of Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸Ellison Institute of Technology, Los Angeles, California, United States
🇺🇸Rocky Mountain Cancer Centers, LLP, Lone Tree, Colorado, United States
Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC
- Conditions
- Cancer of ProstateProstate CancerCastration Resistant Prostatic NeoplasmsProstatic CancerCancer of the ProstateProstate NeoplasmCastrate Resistant Prostate CancerCastration Resistant Prostatic Cancer
- Interventions
- First Posted Date
- 2022-01-13
- Last Posted Date
- 2022-08-05
- Lead Sponsor
- Nuvation Bio Inc.
- Registration Number
- NCT05191017
- Locations
- 🇺🇸
Pennsylvania Cancer Specialists and Research Institute, Gettysburg, Pennsylvania, United States
🇺🇸Gabrail Cancer Center Research, Canton, Ohio, United States
🇺🇸NEXT Virginia, Fairfax, Virginia, United States
Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC
- Conditions
- Advanced Breast CancerBreast TumorMetastatic Breast CancerBreast CarcinomaCancer of the BreastBreast CancerMalignant Tumor of BreastCancer of Breast
- Interventions
- First Posted Date
- 2022-01-13
- Last Posted Date
- 2023-07-11
- Lead Sponsor
- Nuvation Bio Inc.
- Registration Number
- NCT05191004
- Locations
- 🇺🇸
Pennsylvania Cancer Specialists and Research Institute, Gettysburg, Pennsylvania, United States
🇺🇸Pacific Cancer Medical Center, Inc., Anaheim, California, United States
🇺🇸Compassionate Cancer Care Research Inc., Fountain Valley, California, United States